pegylated tissue kallikrein-1 (QHRD106) / Qianhong Bio-Pharma - LARVOL DELTA

Study to Assess the Efficacy and Safety of QHRD106 Injection in Acute Ischemic Stroke. (clinicaltrials.gov) - P2 | N=320 | Recruiting | Sponsor: Changzhou Qianhong Bio-pharma Co., Ltd.

New P2 trial • Cardiovascular • Ischemic stroke

The first-in-human study of QHRD106 functioning as a safe and effective long-acting kallikrein drug potentially aiding ischemic stroke. (PubMed, Expert Opin Investig Drugs) - P1 | "This study provided initial evidence of potential treatment for ischemic strokes that the QHRD106 injection functioned as a safe and effective long-acting kallikrein drug. This study was registered on ClinicalTrials.gov with the identifier NCT06380699 and NCT06388772."

Clinical • Journal • P1 data • Cardiovascular • Ischemic stroke